Chemotherapy with or without trastuzumab

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Oakman, C ^a   Sapino, A ^b   Marchio C ^b   Pestrin, M ^a   Biganzoli, L ^a   di Leo, A ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; HER2; Stage I; T1N0M0; Trastuzumab

Indexed keywords

ANASTROZOLE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG FATALITY; GENE AMPLIFICATION; GENE DOSAGE; GENETIC HETEROGENEITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 78649385299     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq283     Document Type: Conference Paper

References (38)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
4. Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2/neu positive early breast cancer patients. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006; abstract 52.
5. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
6. Spielmann M, Roche H, Delozier T et al. Trastuzumab for patients with axillary node positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 7: 6129-6134.
7. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685-5692.
8. Perez EA, Suman VJ, Davidson NE et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. Cancer Res 2009; 69: abstract 80.
9. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
10. Hanrahan EO, Valero V, Gonzalez-Angulo AM et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 2006; 24: 2113-2122.
11. Rakkhit R, Broglio K, Peintinger F et al. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Cancer Res 2009; 69: abstract 701.
12. Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9: 923-930.
13. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700-5706.
14. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27: 5693-5699.
15. Chia S, Norris B, Speers C et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of nodenegative breast cancers. J Clin Oncol 2008; 26: 5697-5704.
16. Tovey SM, Brown S, Doughty JC et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009; 100: 680-683.
17. Black D, Younger J, Martei Y et al. Recurrence risk in T1a-b, node-negative, HER2 positive breast cancer. Breast Cancer Res Treat 2006; 100: abstract 2037.
18. Park YH, Kim ST, Cho EY et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 2010; 119: 653-661.
19. Fisher B, Bryant J, Dignam JJ et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20: 4141-4149.
20. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
22. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998; 16: 515-521.
23. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008; 26: 1231-1238.
24. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
25. Goldhirsch A, Ingel JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2009; 20: 1319-1329.
26. www.nccn.org/.
27. ClinicalTrials.gov Identifier: NCT00542451.
28. ClinicalTrials.gov Identifier: NCT00593697 (SOLD).
29. ClinicalTrials.gov Identifier: NCT00629278 (SHORT-HER).
30. ClinicalTrials.gov Identifier: NCT00381901 (PHARE).
31. ClinicalTrials.gov Identifier: NCT00712140 (PERSEPHONE).
32. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
33. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537.
34. Miller DV, Jenkins RB, Lingle WL et al. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence insitu hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004; 22(14 Suppl): abstract 568.
35. Sukov WR, Miller DV, Dueck AC et al. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: data from N9831 Intergroup Adjuvant Trial. J Clin Oncol 2009; 27(15 Suppl): abstract 520.
36. Paik S. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358: 1409-1411.
37. Marchiò C, Lambros MB, Gugliotta P et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009; 219: 16-24.
38. Yeh IT, Martin MA, Robetorye RS et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009; 9: 1169-1175.